Welcome to the 561st Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.
The highlights of this week's edition are randomised controlled trials evaluating enteral glutamine for treatment of burn injuries & vilobelimab (an anti-C5a antibody) in invasively mechanically ventilated patients with COVID-19; systematic reviews and meta analyses on adjusted versus fixed doses of LMWHs in trauma patients & corticosteroids in community-acquired pneumonia; and observational studies comparing fully magnetically levitated vs axial-flow left ventricular assist devices at 5 years & outcomes of cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after the acute phase.
There are also guidelines on artificial liver support in patients with liver failure & the management of patients with COVID-19; narrative reviews on acute ischemic stroke in childhood & acute pancreatitis; editorials on data science in the intensive care unit & local anesthetics and erector spinae plane blocks; and commentaries on post-COVID-19 interstitial lung disease & withdrawing life-sustaining therapies and the conundrum of “brain death”.
If you only have time to read one review article this week, try this one on acute respiratory distress syndrome from my colleagues in Belfast.
This week's visual abstract from Jakub Fronczek is on the COCA trial. You can follow us on Instagram to stay current with these superb infographics.
If you missed the launch of our Critical Care Reviews Book 2022 at CCR22, you can find it on the website, along with our previous three books. These summarise, critique and place in context the best critical care trials of each year. They are free to view online or download as a pdf. You can also purchase a print copy at very low cost.
You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.
I hope you find this newsletter useful.
Until next week